LM
MYGN icon

Luminus Management’s Myriad Genetics MYGN Stock Holding History

Luminus Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-122,691
Closed -$1.78M – 28
2022
Q4 		$1.78M Buy
+122,691
New +$2.29M 0.44% 17

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Luminus Management's MYGN Position: Q1 2023 in Review

Luminus Management sold out of Myriad Genetics (MYGN) in Q1 2023, closing a stake of 122,691 shares — an estimated $1.78M sold.

Luminus Management first reported a position in MYGN in Q4 2022 and held it in 1 quarter. The position peaked at $1.78M in Q4 2022. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2023.

  • Luminus Management reported no remaining Myriad Genetics position as of Q1 2023 after selling out during the quarter.
  • Luminus Management sold 122,691 Myriad Genetics shares in Q1 2023, an estimated $1.78M.
  • Luminus Management first reported a position in Myriad Genetics in Q4 2022 and held it in 1 quarter.
  • Luminus Management's Myriad Genetics position peaked at $1.78M in Q4 2022.
  • 190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2023.

Based on Luminus Management's 13F filing for Q1 2023, filed 15 May 2023.